Tissue inhibitor of metalloproteinase-1 timp-1 in colorectal cancer: Correlation with clinico-morphological factors

Voprosy Onkologii

Volumn 55, Issue 2, 2009, Pages 171-176

  Korotkova, Y A ^a   Gerstein, Ye S ^a   Prorokov, V V ^a   Kushlinky, N Ye ^a   Blokhin, N N ^a  

^a INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR MARKER;

ADVANCED CANCER; ARTICLE; CANCER INVASION; CANCER LOCALIZATION; CANCER PATIENT; CANCER SURGERY; COLORECTAL CANCER; CORRELATION ANALYSIS; DISEASE MARKER; DISTANT METASTASIS; ENZYME ANALYSIS; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME SYNTHESIS; HISTOPATHOLOGY; HUMAN; INTESTINE MUCOSA; MAJOR CLINICAL STUDY; PLASMA;

ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TUMOR MARKERS, BIOLOGICAL;

EID: 67049108507     PISSN: 05073758     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Russian source
2. Russian source
3. Baker E.A., Leaper D.J. The plasminogen activator and matrix metalloproteinase systems in colorectal cancer: relationship to tumour pathology // Europ. J. Cancer.-2003.-Vol.39.-P. 981-988.
4. Deryugina E.I., Quigley J.P. Matrix metalloproteinases and tumor metastasis // Cancer Metastasis Rev.-2006.-Vol. 25.-P. 9-34.
5. Duffy M.J., McGowan P.M., Gallagher W.M. Cancer invasion and metastasis: changing views // J. Pathol.-2008.-Vol. 214.-P. 283-293.
6. Emenaker N.J., Calaf G.M., Cox D. et al. Short-chain fatty acids inhibit invasive human colon cancer by modulating uPA, TIMP-1, TIMP-2, mutant p53, Bcl-2, Bax, p21 and PCNA protein expression in an in vitro cell culture model// J. Nutr-2001.-Vol. 131 (11 Suppl.).-P.3041S-3046S.
7. Hammer J.H., Basse L, Svendsen M.N. et al. Impact of elective resection on plasma TIMP-1 levels in patients with colon cancer // Colorectal. Dis.-2006.-Vol. 8.-P. 168-172.
8. Hanke B., Wein A., Martus P. et al. Serum markers of matrix turnover as predictors for the evolution of colorectal cancer metastasis under chemotherapy // Brit. J. Cancer.-2003.-Vol. 88.-P. 1248-1250.
9. Hewitt R.E., Brown K.E., Corcoran M., Stetler-Stevenson W.G. Increased expression of tissue inhibitor of metal-loproteinases type 1 (TIMP-1) in a more tumourigenic colon cancer cell line // J. Pathol.-2000.-Vol. 192.-P. 455-459.
10. Hilska M., Roberts P.J., Collan YU. et al. Prognostic significance of matrix metalloproteinases-1, -2, -7 and -13 and tissue inhibitors of metalloproteinases-1, -2, -3 and -4 in colorectal cancer // Int. J. Cancer.-2007.-Vol. 121.-P. 714-723.
11. Holten-Andersen M.N., Hansen U., Brunner N. et al. Localization of tissue inhibitor of metalloproteinases 1 (TIMP-1) in human colorectal adenoma and adenocarcinoma//Int. J. Cancer.-2005.-Vol. 113.-P. 198-206.
12. Holten-Andersen M.N., Stephens R.W., Nielsen H.J. et al. High preoperative plasma tissue inhibitor of metal-loproteinase-1 levels are associated with short survival of patients with colorectal cancer // Clin. Cancer Res.-2000.-Vol. 6.-P. 4292-4299.
13. Islekel H., Oktay G., Terzi C. et al. Matrix metalloproteinase-9,-3 and tissue inhibitor of matrix metalloproteinase-1 in colorectal cancer: relationship to clinicopathological variables // Cell Biochem. Funct.-2007.-Vol. 25.-P. 433-441.
14. Kim T.D., Song K.S., Li G. et al. Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer // BMC Cancer.-2006.-Vol. 6.-P. 211.
15. Kirman I., Jain S., Cekic V. et al. Altered plasma matrix metalloproteinase-9/tissue inhibitor of matrix [corrected] metalloproteinase-1 concentration during the early postoperative period in patients with colorectal cancer // Surg. Endosc-2006 -Vol. 20.-P. 482-486.
16. Lubbe W.J., Zhou Z.Y, Fu W. et al. Tumor epithelial cell matrix metalloproteinase 9 is a target for antimetastatic therapy in colorectal cancer // Clin. Cancer Res.-2006,-Vol. 12.-P. 1876-1882.
17. Nelson A.R., Fingleton B., Rothenberg M.L., Matrisian L.M. Matrix metalloproteinases: biologic activity and clinical implications//J. Clin. Oncol.-2000.-Vol. 18.-P. 1135-1149.
18. Oba K., Konno H., Tanaka T. et al. Prevention of liver metastasis of human colon cancer by selective matrix metalloproteinase inhibitor MMI-166 // Cancer Lett.-2002,-Vol. 175.-P. 45-51.
19. Ramnath N., Creaven P.J. Matrix metalloproteinase inhibitors // Curr. Oncol. Rep.-2004.-Vol. 6.-P. 96-102.
20. Tutton M.G., George M.L., Eccles S.A. et al. Use of plasma MMP-2 and MMP-9 levels as a surrogate for tumour expression in colorectal cancer patients // Int. J. Cancer.-2003.-Vol. 107.-P. 541-550.
21. Wang L, Chen W., Xie X. et al. Celecoxib inhibits tumor growth and angiogenesis in an orthotopic implantation tumor model of human colon cancer // Exp. Oncol.-2008.-Vol.30.-P. 42-51.
22. Wang W.S., Chen P.M., Su Y Colorectal carcinoma: from tumorigenesis to treatment // Cell Mol. Life Sci.-2006.-Vol.63.-P. 663-671.
23. Yamauchi K., OgataY, Nagase H., Shirouzu K. Inhibition of liver metastasis from orthotopically implanted colon cancer in nude mice by transfection of the TIMP-1 gene into KM12SM cells // Surg. Today.-2001.-Vol. 31.-P. 791-798.
24. Yukawa N., Yoshikawa T, Akaike M. et al. Impact of plasma tissue inhibitor of matrix metalloproteinase-1 on long-term survival in patients with colorectal cancer // Oncology.-2007,-Vol. 72 (3-4).-P. 205-208.
25. Zucker S., Cao J., Chen W.T. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment//Oncogene.-2000.-Vol. 19.-P. 6642-6650.
26. Zucker S., Vacirca J. Role of matrix metalloproteinases (MMPs) in colorectal cancer // Cancer Metastasis Rev.-2004.-Vol. 23 (1-2).-P. 101-117.